| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors
|
Isakoff, S.J.
|
|
|
31 |
5 |
p. 626-633
|
artikel
|
| 2 |
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
|
Kolinsky, M.P.
|
|
|
31 |
5 |
p. 619-625
|
artikel
|
| 3 |
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer ☆
|
Planchard, D.
|
|
|
31 |
5 |
p. 609-618
|
artikel
|
| 4 |
Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019
|
Bosetti, C.
|
|
|
31 |
5 |
p. 558-568
|
artikel
|
| 5 |
Assisted suicide, euthanasia, or more need for palliative care?
|
Mercadante, S.
|
|
|
31 |
5 |
p. 659
|
artikel
|
| 6 |
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas ✰
|
Schoenfeld, A.J.
|
|
|
31 |
5 |
p. 599-608
|
artikel
|
| 7 |
Corrigendum to ‘Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models’
|
Ny, L.
|
|
|
31 |
5 |
p. 663
|
artikel
|
| 8 |
Editorial Board
|
|
|
|
31 |
5 |
p. v
|
artikel
|
| 9 |
European cancer mortality predictions for the year 2020 with a focus on prostate cancer
|
Carioli, G.
|
|
|
31 |
5 |
p. 650-658
|
artikel
|
| 10 |
Height as a mediator of sex differences in cancer risk
|
Fu, B.C.
|
|
|
31 |
5 |
p. 634-640
|
artikel
|
| 11 |
Hepatic sinusoidal obstruction syndrome induced by nivolumab in advanced melanoma: a case report
|
Charvet, E.
|
|
|
31 |
5 |
p. 661-662
|
artikel
|
| 12 |
Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with ∼430 000 women
|
Murphy, N.
|
|
|
31 |
5 |
p. 641-649
|
artikel
|
| 13 |
Managing COVID-19 in the oncology clinic and avoiding the distraction effect
|
Cortiula, F.
|
|
|
31 |
5 |
p. 553-555
|
artikel
|
| 14 |
Mise en place: toward neoadjuvant chemoimmunotherapy for early triple-negative breast cancer
|
van Dongen, M.G.J.
|
|
|
31 |
5 |
p. 556-557
|
artikel
|
| 15 |
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer
|
Adams, S.
|
|
|
31 |
5 |
p. 582-589
|
artikel
|
| 16 |
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
|
Schmid, P.
|
|
|
31 |
5 |
p. 569-581
|
artikel
|
| 17 |
RASAL2-RET: a novel RET rearrangement in a patient with high-grade sarcoma of the chest
|
Zhou, Y.
|
|
|
31 |
5 |
p. 659-661
|
artikel
|
| 18 |
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
|
Waks, A.G.
|
|
|
31 |
5 |
p. 590-598
|
artikel
|
| 19 |
Table of Contents
|
|
|
|
31 |
5 |
p. iii-iv
|
artikel
|
Tijdschrift beschrijving